Cargando…

Nanoparticle T cell engagers for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%. The standard-of-care for AML has not changed in the past few decades. Promising immunotherapy options are being developed for the treatment of AML; yet, these regimens require highly laborious and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhallak, Kinan, Sun, Jennifer, Muz, Barbara, Jeske, Amanda, Yavner, Jessica, Bash, Hannah, Park, Chaelee, Lubben, Berit, Adebayo, Ola, Achilefu, Samuel, DiPersio, John F., Azab, Abdel Kareem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448516/ https://www.ncbi.nlm.nih.gov/pubmed/34548905 http://dx.doi.org/10.18632/oncotarget.28054

Ejemplares similares

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022)

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2021)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

Targeting E-selectin to Tackle Cancer Using Uproleselan
por: Muz, Barbara, et al.
Publicado: (2021)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
por: Muz, Barbara, et al.
Publicado: (2015)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

The myeloid binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting
por: Lu, Zhi Hong, et al.
Publicado: (2014)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
por: Petti, Allegra A., et al.
Publicado: (2022)

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET
por: Ghai, Anchal, et al.
Publicado: (2021)

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019)

Myeloid Leukemias: A Glance at Middle Eastern Centers
por: Khaled, Safaa AA, et al.
Publicado: (2019)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)

Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing
por: Hughes, Andrew E. O., et al.
Publicado: (2014)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

Mouse models of graft-versus-host disease: advances and limitations
por: Schroeder, Mark A., et al.
Publicado: (2011)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
por: Bono, Silvia, et al.
Publicado: (2018)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Integrin Regulation of CAF Differentiation and Function
por: DiPersio, C. Michael, et al.
Publicado: (2019)

Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells
por: Hallal, Rawan, et al.
Publicado: (2020)

Regulation of fibulin-2 gene expression by integrin α3β1 contributes to the invasive phenotype of transformed keratinocytes
por: Missan, Dara S., et al.
Publicado: (2014)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tk3l06brlt398orv0i8s6nc5l9